Veraxa Biotech AG (VRXA)

NASDAQ: VRXA · USD

$0.99

-0.04 (-3.9%)· Recorded snapshot

Market cap	140M
Revenue (ttm)	29.5K
Net income (ttm)	-84M
EPS (ttm)	-$5.80
Shares out	141.4M
Volume	53,497.072
Beta	0.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 29.5K
Net income (ttm): -84M
EPS (ttm): -$5.80
Market cap: 140M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-871.4

P25 n/aP50 n/aP75 n/a

ROIC-478.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VRXA indicators

Market & fundamental data

Available fields

161

Groups with data

Currency

CHF

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002079109
Company name	Veraxa Biotech AG
Country	Germany
Country code	US
Enterprise value	$139.4M
Exchange	NASDAQ
Financial currency	CHF
First seen	2026-07-12
Fiscal year end	December
Founded	2021
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	CH1476899161
Last 10-K release date	2026-06-16
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$140M
Market cap category	Micro-Cap
Options	No
Price	$0.99
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	VRXA
Website	https://www.veraxa.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-586.23%
EV/Sales	4,718.44x
FCF / EV yield	-9.07%
FCF yield	-9.03%
P/S ratio	4,738.64x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	66%
Operating margin	-282,661.28%
Pretax margin	-286,033.66%
ROA	-49.99%
ROCE	-89.23%
ROE	-871.42%
ROIC	-478.61%
SBC / revenue	224,805.89%
Tax / revenue	-1,675.92%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-534,715
Depreciation and amortization	$2.4M
EBIT	$-83.5M
EBITDA	$-81M
EPS	$-5.80
FCF per share	$-0.09
Financing cash flow	$8.3M
Free cash flow	$-12.6M
Free cash flow minus SBC	$-77.1M
Gross profit	$19,498
Income taxes	$-495,117
Investing cash flow	$-551,329
Net borrowing	$1M
Net cash flow	$-4.7M
Net income	$-84M
Operating cash flow minus SBC	$-76.5M
Operating income	$-83.5M
Revenue	$29,543
Stock-based compensation	$66.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-2.78
Book value per share	$-1.35
Goodwill	$27.9M
Interest coverage	-18,644.03
Long-term assets	$98.4M
Long-term liabilities	$113.7M
Net cash (debt)	$596,937
Net cash / market cap	0.43%
Piotroski F-Score	1
Property, plant and equipment	$3.8M
Shareholders' equity	$-19.9M
Tangible book value	$-114.2M
Tangible book value per share	$-7.74
Total assets	$101.9M
Total cash	$2M
Total debt	$1.4M
Total liabilities	$121.8M
WACC	5.39%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$3.5M
Current liabilities	$8.1M
Current ratio	0.44
Net working capital	$-6.4M
Quick ratio	0.42
Working capital	$-4.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$5.53
1D price change	-3.88%
1M price change	-12.39%
1M total return	-12.39%
1W price change	-0.97%
1W total return	-0.97%
1Y price change	-90.59%
1Y return CAGR	-90.6%
1Y total return	-90.59%
20-day SMA	$1.08
200-day SMA	$6.88
3M price change	-43.75%
3M total return	-43.75%
50-day SMA	$1.29
50-day SMA vs 200-day SMA	50under200
52-week high	$27.36
52-week high date	2026-06-11
52-week low	$0.95
52-week low date	2026-10-26
6M price change	-92.22%
6M total return	-92.22%
After-hours change	1.01%
After-hours close	$0.99
After-hours price	$1.00
All-time high	$27.36
All-time high date	2026-06-11
All-time low	$0.95
All-time low date	2026-10-26
Average true range (ATR)	$0.12
Average volume	303.9K
Beta (1Y)	0.61
Beta (2Y)	0.23
Beta (5Y)	0.22
Change from 52-week high	-96.38%
Change from 52-week low	4.21%
Change from all-time high	-96.38%
Change from all-time low	4.21%
Change from open	-2.94%
Day's gap	-0.97%
Dollar volume	$52,962
High price	$1.06
Low price	$0.96
Monthly RSI	15.49
Open price	$1.02
Position in 52-week range	29.88%
Premarket change	6.06%
Premarket close	$0.99
Premarket price	$1.05
Previous close	$1.03
Price vs 150-day SMA	-82.11%
Price vs 20-day SMA	-8.16%
Price vs 200-day SMA	-85.6%
Price vs 50-day SMA	-23.49%
Relative volume	0.18
RSI	39.43
Sharpe ratio	-0.99
Sortino ratio	-1.3
Volume	53.5K
Weekly RSI	34.42
YTD price change	-90.72%
YTD total return	-90.72%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	36.8M
Float percentage	26.02%
Shares held by insiders	41.51%
Shares held by institutions	0.46%
Shares outstanding	141.4M
Short % of float	0.29%
Short % of shares	0.08%
Short ratio	0.5 days

Deeper analysis on VRXA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VRXA report

Is a complete VRXA research report available?

No complete published report is available for Veraxa Biotech AG (VRXA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Veraxa Biotech AG (VRXA)

Price

Financial snapshot

Fair-value bridge

Latest news · VRXA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VRXA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VRXA

Frequently asked questions